| This week's sponsor is CMIC Group. | | | Considering Japanese Market Entry?
As Japan's largest CRO with end-to-end solution, CMIC Group is your most experienced partner in Japan & the US. Our experts will help you determine the best strategy at any stage of drug development.
Click here to learn more! |
Today's Rundown Ipsen strikes $1.3B Clementia buyout to boost rare disease unit Novartis pays $150M to license Akcea-Ionis cardiac disease drug Autolus taps Vineti to help deliver personalized cell therapies [Sponsored] Rise in Targeted Therapies Drives Need for Flexible, Small-Volume Manufacturing Mallinckrodt inks photopheresis R&D pact with specialist Transimmune [Sponsored] Preventing Unnecessary Exposure to Opioids After Surgery Roche bulks up in gene therapy and hemophilia with $4.3B Spark buyout Featured Story | | | Monday, February 25, 2019 Ipsen has struck a $1.3 billion (€1.1 billion) deal to buy Clementia Pharmaceuticals for its late-phase rare disease drug palovarotene. The transaction will see Ipsen hand over $1 billion upfront to acquire the retinoic acid receptor gamma agonist ahead of a filing for FDA approval. |
|
|
| This week's sponsor is Sprout BioVentures. | | | Final Week for Golden Sprout Competition
Don’t miss out on 6 months of chemistry support at no cost. Strengthen your chemical starting points and work with a world-class research organization trusted by global biopharma. Click here to download the application. |
Top Stories Monday, February 25, 2019 Novartis has taken up its option to license antisense oligonucleotide TQJ230, triggering a $150 million payout that Akcea Therapeutics will share with Ionis Pharmaceuticals. The decision sets Novartis up to test the RNA-targeting drug in a phase 3 cardiovascular outcomes trial. Monday, February 25, 2019 Autolus has a lot of CAR-T candidates heading for clinical trials and has teamed up with software company Vineti to try to bring them to market more safely and efficiently. Monday, February 25, 2019 Biologics have experienced steady double-digit growth over the last 15 years and now comprise slightly more than a quarter of all New Molecular Entity (NME) FDA approvals. Monday, February 25, 2019 Mallinckrodt is joining forces with Transimmune on extracorporeal photopheresis research with hopes to expand the treatment beyond skin symptoms linked to cutaneous T-cell lymphoma. Monday, February 18, 2019 The opioid crisis continues to dominate the headlines and while many solutions are being discussed, prevention is often overlooked. Reducing exposure to opioids after surgery through better pain management options can make an impact. Monday, February 25, 2019 Late-to-the-game Roche has finally made a move in gene therapy, one of the biopharma industry’s most sought-after and expensive classes of medications, by snatching up Spark Therapeutics for $4.3 billion—gaining some novel hemophilia treatments to complement Hemlibra along the way. Resources Sponsored by: Blue Matter White paper outlining the key types of cell-based immunotherapies in oncology, as well as the development and commercial outlook for each. Sponsored by: AlphaSense It’s never been more challenging to stay on top of trends and innovation shaping the future of healthcare. Discover how AI can help competitive intelligence teams achieve more proactive strategies. Sponsored by: Patheon, part of Thermo Fisher Scientific When a biologics company prepares to launch a new product, it must forecast the manufacturing capacity it will need, factoring in its estimate of the size of future sales, the timing of the launch, the dosage of the product, its strategy for building its market and a host of other variables. Sponsored by: Oracle Health Sciences 92% of survey respondents make changes to their RTSM/IRT systems due to study changes. See what else puts a strain on their clinical trials. Download the Research Whitepaper. Sponsored by: Patheon, part of Thermo Fisher Scientific Download this whitepaper to learn more. Sponsored by: The Kinetix Group Explore how the pharma industry can adapt its approach to the changing healthcare marketplace in the era of the Quadruple Aim Sponsored by: Cofactor Genomics Learn how Health Expression Models provide increased sensitivity, specificity, and accuracy for characterizing immune response in solid tumor specimens. Sponsored by: BioAnalytix, Inc. This whitepaper reviews fundamental aspects of HCPs that pertain to biologic drug development and presents current and emerging approaches to HCP analysis. Sponsored by: Veradigm Clinical trials take too long and cost too much—here's what needs to change. Sponsored by: Outer Edge Technology With FDA approval imminent, start-up Life Sciences company partners with an industry focused MSP to design and manage its regulated cloud-based infrastructure to speed time to market. Presented by: Veeva Share your thoughts on the life sciences industry's progress in improving study execution. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. BIO Asia International Conference March 5-6, 2019 | Grand Hyatt Tokyo | Tokyo, Japan PEGS: The Essential Protein Engineering Summit April 8 – 12, 2019 | Boston, MA Middle East Life Sciences Compliance Training April 29, 2019 – May 2, 2019 | Dubai U.A.E. 2019 BIO International Convention June 3-6, 2019 | Philadelphia, PA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! | 